European Commission approves Tecentriq + Avastin and chemotherapy for the initial treatment of specific types of metastatic lung cancer

Roche has announced that the European Commission has approved and granted marketing authorisation for Tecentriq (atezolizumab) in combination with Avastin (bevacizumab), paclitaxel and carboplatin, for the first-line treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC). In people with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with Avastin, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.

This approval includes EGFR mutant or ALK-positive non-small cell lung cancer after failure of a targeted therapy marking a first for this subgroup of patients, in which there is a significant need for alternative treatment options.

This approval is based on results from the Phase III IMpower150 study, which showed that Tecentriq in combination with Avastin and chemotherapy helped people live significantly longer, compared with Avastin and chemotherapy (median overall survival [OS]=19.8 versus 14.9 months; hazard ratio [HR]=0.76; 95% CI: 0.63–0.96; p=0.006) in the intention-to-treat (ITT) population. The safety profile of the Tecentriq combination was consistent with that observed in previous studies.